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Aims: Brugada syndrome (BrS) is an inherited cardiac arrhythmia with an increased risk
for sudden cardiac death (SCD). About 20% of BrS cases are explained by mutations in
the SCN5A gene, encoding the main cardiac sodium Nav1.5 channel. Here we present
a severe case of cardiac sodium channelopathy with BrS caused by SCN5A compound
heterozygous mutations. We performed a genetic analysis of SCN5A in a male proband
who collapsed during cycling at the age of 2 years. Because of atrial standstill, he received
a pacemaker, and at the age of 3 years, he experienced a collapse anew with left-sided
brain stroke. A later ECG taken during a fever unmasked a characteristic BrS type-1
pattern. The functional effect of the detected genetic variants was investigated.
Methods and Results: Next-generation sequencing allowed the detection of
two SCN5A variants in trans: c.4813+3_4813+6dupGGGT—a Belgian founder
mutation—and c.4711 T>C, p.Phe1571Leu. A familial segregation analysis
showed the presence of the founder mutation in the proband’s affected father
and paternal aunt and the de novo occurrence of the p.Phe1571Leu. The functional
effect of the founder mutation was previously described as a loss-of-function.
We performed a functional analysis of the p.Phe571Leu variant in HEK293 cells
alone or co-expressed with the β1-subunit. Compared to the SCN5A wild type,
p.Phe1571Leu displayed a hyperpolarizing shift in the voltage dependence of
inactivation (loss-of-function), while the activation parameters were unaffected.
Using the peptide toxin nemertide α-1, the variant’s loss-of-function effect
could be restored due to a toxin-dependent reduction of channel inactivation.
Nijak et al. Functional Characterization of p.Phe1571Leu in SCN5A
Conclusion: This is the first report providing support for the pathogenicity of the
p.Phe1571Leu SCN5A variant which, together with the c.4813+3_4813+6dupGGGT
founder mutation, explains the severity of the phenotype of cardiac sodium
channelopathy with BrS in the presented case.
Keywords: Brugada syndrome, cardiac arrhythmia, SCN5A, case report, compound heterozygosity
INTRODUCTION
Brugada syndrome (BrS) is an inherited cardiac arrhythmia
with a significant risk for sudden cardiac death (SCD) and a
prevalence of 1:2,000 in the general population (1). The disease
is diagnosed based on a specific ECG pattern with distinct
ST-segment elevation in the right precordial leads (2, 3). The
disorder is predominantly explained bymutations in SCN5A (20–
25% of all cases), encoding the α-subunit of the cardiac voltage-
gated sodium channel Nav1.5. Currently, over 20 genes encoding
other cardiac channels as well as their accessory proteins are
linked to BrS (2, 4, 5).
Cardiac action potential generation and conduction velocity
in the ventricles rely primarily on the availability of Nav1.5
channels (3, 6), responsible for a fast depolarization of the
cardiomyocyte membrane (7, 8). Nav1.5 is a pseudo-tetramer
consisting of four repetitive transmembrane domains (DI–IV),
containing six transmembrane-spanning segments each (S1–
S6), with segments S1–S4 forming the ‘voltage sensing domain
(VSD)’. The VSDs of DI to DIII control the channel opening
and closure (activation process), whereas the VSD of DIV
regulates the channel inactivation (3, 9, 10). An accessory
β1-subunit binds covalently to the α-subunit, with variable
effects on the activation kinetics (11). BrS is associated with
a loss-of-function of Nav1.5, resulting in reduced sodium
current (INa), impaired channel kinetics, or trafficking (3–
5). Several reports show that heterozygous SCN5A variants
cause a BrS phenotype with variable expressivity, ranging from
asymptomatic to recurrent arrhythmias and SCD. In addition,
they can lead to cardiac conduction disease, sick sinus syndrome,
dilated cardiomyopathy, and familial atrial fibrillation or an
“overlap syndrome” of these entities, together grouped as cardiac
sodium channelopathies. Interestingly, second-hit mutations in
genes encoding the auxiliary subunits of Nav1.5 or compound
heterozygous mutations in SCN5A tend to cause more severe
phenotypes (4–6).
Here we present a patient with a severe phenotype of cardiac
sodium channelopathy with BrS phenotype presenting in early
childhood due to compound heterozygous SCN5A mutations.
One of the variants, c.4813+3_4813+6dupGGGT—a Belgian
founder mutation causing cardiac conduction defects and/or BrS
in 83% of carriers (Sieliwonczyk et al., under review), segregates
in the paternal family. This splice site mutation results in the
deletion of 32 amino acids (1,572 to 1,604) in S2 and S3 of
DIV of Nav1.5 with a loss-of-function of the channel, which is
observed as the absence of sodium current when expressed in
human embryonal kidney TSA cells (12, 13). We hypothesize
that the second de novo variant, c.4711T>C (p.Phe1571Leu),
located in S2 of DIV, aggravates the phenotype in the proband.
In this study, we functionally characterize this p.Phe1571Leu
variant. We provide evidence for a loss-of-function effect which,
in co-occurrence with the Belgian founder mutation, most likely
explains the severity of the observed phenotype.
MATERIALS AND METHODS
Mutation Analysis of SCN5A
Genomic DNA was extracted from whole blood using standard
procedures. Genetic testing of SCN5A was performed using an
in-house developed cardiac arrhythmia gene panel (14). Sanger
sequencing was used to validate the variants and perform familial
segregation analysis. This study was carried out in accordance
with the recommendations of the Ethics Committee of Antwerp
University Hospital. All subjects gave written informed consent
in accordance with the Declaration of Helsinki.
Site-Directed Mutagenesis and
Transfection of HEK293 Cells
WT human SCN5A cDNA was cloned into the pSP64T
plasmid and human SCN1B (the β1-subunit) cDNA into a
pRcCMV plasmid. The p.Phe1571Leu variant was introduced
in SCN5A using the QuickChange Site-Directed Mutagenesis
Kit (Life Technologies) and a primer set that contained the
variant (Eurogentec S.A.). The variant SCN5A p.Phe1571Leu
plasmid was obtained by amplification in XL2 blue cells
(Agilent Technologies) and subsequently purified (purification
kit, Macherey-Nagel). The presence of the desired and absence
of additional mutation(s) was confirmed by sequencing.
HEK293 cells were transiently transfected with WT SCN5A
(expressing Nav1.5) or the p.Phe1571Leu variant (Nav1.5-
F1571L) alone or co-expressed in a 1:1 mass ratio with
SCN1B using Lipofectamine 2000 (Life Technologies). In
every condition, the pEGFP1-N1 plasmid was co-transfected
to visualize the transfected cells for electrophysiological
analysis. The cells were grown in Dulbecco’s Modified Eagle
Medium supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (Life Technologies). The cells were
placed in a 5% CO2 incubator at 37
◦C for 48 h prior to the
patch-clamp recordings.
Electrophysiological Recordings
Whole-cell patch-clamp recordings were performed at room
temperature (20–22◦C) using an Axopatch 200B amplifier
and a pClamp 10.7/Digidata 1440A acquisition system (Axon
Molecular Devices). Patch-pipettes with a resistance between
1 and 1.5 M were pulled from 1.2-mm borosilicate glass
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capillaries (World Precision Instruments, Inc.) using a P-2000
puller (Sutter Instrument Co.). The pipettes were filled with an
intracellular solution containing (in mM): 4 NaCl, 106 KCl, 5
K2ATP, 2 MgCl2, 5 K4BAPTA, and 10 HEPES adjusted to pH
7.2 with KOH. The cells were continuously superfused with
a bath solution (ECS) containing (in mM): 145 NaCl, 4 KCl,
5.3 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose (pH 7.35 with
NaOH). For the toxin experiments, the nemertide 1-α synthetic
peptide was directly dissolved in ECS at a concentration of
5µM and applied near the patched cell using a pressurized
fast-perfusion system.
INa was recorded by step depolarization for 20ms to
different potentials between −120 and +40mV, from a holding
potential of −130mV. Current–voltage relations (in pA/pF)
were obtained by normalizing the peak INa amplitude to the
cell capacitance and plotting these values as a function of
the applied potential. Normalized conductance–voltage (G–
V) curves were obtained by approximating the linear part
of the current–voltage relation with the function I =
G∗max(Vapplied − Vreversal) to determine the maximal conductance
Gmax. Dividing the data points of the current–voltage relation
by the calculated maximum current at that voltage, using
Gmax, yielded the G–V relation. Activation and inactivation
kinetics were determined by fitting the activating part or
decay of INa with a single exponential function. The voltage
dependence of inactivation was determined by stepping after
a 500-ms pre-pulse, ranging from −135 to −30mV, to a
−10-mV test pulse to determine the amount of channel
inactivation. The voltage dependence of the inactivation curves
were obtained by plotting the normalized INa amplitude upon
the test pulse against the corresponding pre-pulse potential.
The recovery from inactivation was investigated upon a 500-
ms conditioning pre-pulse to induce inactivation. The recovery
was determined by stepping after the pre-pulse for variable
time to −130mV, a potential that recovers inactivation, followed
by −10mV pulse to evaluate the INa amplitude, which is a
measure for the channels that have recovered. The speed of
recovery from inactivation was evaluated by normalizing the INa
elicited upon the −10mV pulse to the maximum INa. These
normalized values were plotted as a function of the duration
at −130mV, and this relation was approximated with a single
exponential function.
Currents, after passing a 5-kHz low-pass filter, were
digitized at a sampling rate of 10 kHz. Recordings were
discarded from analysis if the remaining voltage error,
originating from series resistance error, exceeded 5mV
after compensation.
Data Analysis
To obtain the midpoint potential (V1/2) and the slope factor
(Vs) for the voltage dependence of activation and of inactivation,
the G–V and voltage dependence of the inactivation curves were




Data are reported as mean ± standard error of mean (SEM)
with n as the number of cells analyzed. A comparison between
the WT and the variant was performed with two-tailed Student’s
t-test. A P-value of ≤0.05 indicates statistical significance (Systat
Software Inc.).
CASE DESCRIPTION AND DIAGNOSTIC
ASSESSMENT
Clinical Presentation of Index Patient and
Available Family Members
A 20-months-old boy was admitted to a hospital emergency
service after his collapse during cycling. Based on the ECG, he
was diagnosed with sick sinus syndrome (SSS) with junctional
escape (Figure 1B). A DDD-pacemaker was implanted, and
during the implantation, the dilated atria were electrically
inactive, leading to the diagnosis of atrial standstill. A DNA
sample was collected for molecular diagnostics.
During recovery, he experienced a collapse anew, caused
by a thrombus which led to a left-sided brain stroke.
The echocardiography showed left atrial spontaneous
echocardiographic contrast but no obvious thrombi. Although
during follow-up no ventricular tachyarrhythmias were
documented, an ECG taken during fever (39◦C) unmasked
the characteristic BrS type-1 pattern (Figure 1C), and the boy
received an endovascular VVI-ICD as there is a high estimated
risk of developing ventricular arrhythmias (timeline: Figure 1A).
The father had a history of syncope at the age of 30.
His ajmaline challenge test was negative, but an ECG taken
during a fever episode showed a BrS coved-shape ECG pattern
(Figures 1D,E). The sister of the father was diagnosed with an
ajmaline-induced BrS type-1 ECG pattern (Figure 1F).
Molecular Genetics
Two SCN5A variants were identified in the index patient:
c.4813+3_4813+6dupGGGT, a Belgian founder mutation, and
c.4711T>C p. (Phe1571Leu). Since both SCN5A variants are
separated by only 102 base pairs, we could derive from the
sequence reads that they are never located on the same allele (in
trans). No other variants of interest were detected with the PED
MASTR Plus gene panel. A familial segregation analysis revealed
the founder mutation in the proband’s father (II:3) and paternal
aunt (II:2) and de novo occurrence of the p.Phe1571Leu variant
in the index patient (III:1) (Figure 1G).
The founder mutation was previously shown to cause a
loss-of-function of the Nav1.5 channel (13) and is classified
as a pathogenic variant (15). p.Phe1571Leu is absent from the
GnomAD database [gnomad.broadinstitute.org (16)], whereas
one carrier is reported in the TOPMED sample collection
(dbSNP rs1369632373; nhlbiwgs.org). Phenylalanine at position
1,571 is highly conserved between species (Figure 2A), and
in silico prediction on the functional impact of the variant
is possibly damaging (MutationTaster, SIFT, PolyPhen;
ENST00000413689.5). This initially led to the classification
of this variant as a variant of uncertain significance (VUS) (15).
Electrophysiological Characteristics
To determine if this VUS contributes to the severe phenotype
observed in our index patient, the Nav1.5WT andNav1.5-F1571L
variant and combinations with the WT β1-subunit (Nav1.5 +
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FIGURE 1 | (A) Timeline of diagnostic interventions for the described case. ECG traces of (B) the proband on the day of diagnosis with absent atrial activity with
junctional escape, (C) repeated during fever at 39◦C which unmasked BrS ECG pattern with elevated ST segment, (D) the father carrying the SCN5A founder
mutation with absent BrS ECG type-1 pattern after ajmaline challenge, but (E) present during fever at 39◦C (visible in lead V1), and (F) the asymptomatic aunt carrying
theSCN5A founder mutation with ECG type-1 pattern after ajmaline challenge. (G) Pedigree of the family showing the segregation of the identified variants. Full
symbols indicate the affected individuals. The red plus and minus symbols indicate, respectively, the presence or the absence of the variant indicated on the left side
of the pedigree.
β1 and Nav1.5-F1571L + β1) were expressed in HEK293 cells to
assess the functional effect of the variant. The current–voltage (I–
V) relationship showed that the current densities for the Nav1.5
and Nav1.5-F1571L, either expressed alone or in presence of
β1, did not differ (Figures 2B,C). The activation kinetics as well
as the voltage dependence of channel activation (G–V curves)
did not show significant differences, yielding a V1/2 of −13.8
± 1.7 and −14.9 ± 0.9mV, with slope factors of 14.5 ± 2.4
and 14 ± 1.3mV for Nav1.5 and Nav1.5-F1571L, respectively
(Figures 2D,E). These values did not change significantly in
the presence of β1, yielding G–V curves with a V1/2 of −12
± 0.8 and −14.7 ± 1.1mV, with slope factors of 16.1 ± 1
and 11.7 ± 1.7mV for Nav1.5 + β1 and Nav1.5-F1571L +
β1, respectively.
We subsequently analyzed the kinetics of inactivation,
the voltage dependence of inactivation, and the recovery
from inactivation (Figures 3A–E). From the inactivation time
constant, we observed a 3-fold slower inactivation (P< 0.001) for
the variant (1.96 ± 0.12ms at 0mV, n = 7) compared to Nav1.5
WT (0.67 ± 0.08ms at 0mV, n = 8) (Figure 3B). Co-expression
with β1 did not compensate this slowing, and Nav1.5-F1571L +
β1 (2.25 ± 0.16ms at 0mV, n = 9) displayed 3.6-fold slower
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FIGURE 2 | (A) Schematic representation of the Nav1.5 structure (10) with location of the p.Phe1571Leu variant (big full red circle) and p.Arg1632His (small red circle).
The alignment shows the conservation of Phe at position 1571 in SCN5A amino acid sequence between species. The accession numbers for the UniProt database
are indicated on the left side. (B) Electrophysiological properties of WT Nav1.5 and Nav1.5-F1571L alone or co-expressed with β1. Displayed from left to right are the
representative whole-cell ionic current recordings of WT Nav1.5, Nav1.5-F1571L, WT Nav1.5 + β1, and Nav1.5-F1571L + β1. The Na
+-selective currents were elicited
with the pulse protocol shown on the left above the traces. The horizontal bar at the beginning of the traces indicates zero current level. (C) Current density of WT
Nav1.5 (black circles, n = 8), WT Nav1.5 + β1 (gray circles, n = 9), Nav1.5-F1571L (full red inverted triangles, n = 7), and Nav1.5-F1571L + β1 (open red inverted
triangles, n = 9) were obtained by normalizing the peak current amplitudes from pulse protocols shown in (B) to the cell capacitance. (D) Voltage dependence of
channel activation, G–V curves, are represented for WT Nav1.5, Nav1.5-F1571L, WT Nav1.5 + β1, and Nav1.5-F1571L + β1. (E) The voltage-dependent kinetics of
channel activation are shown as means ± SEM.
inactivation kinetics compared to WT (0.63 ±0.02ms at 0mV,
n= 9) (P < 0.001).
Interestingly, the Nav1.5-F1571L variant displayed a
significant 18-mV hyperpolarizing shift in the voltage
dependence of inactivation compared to WT (P = 0.001),
yielding inactivation curves with a V1/2 of −104 ± 3mV (n
= 9) and −86 ± 3mV (n = 5), combined with a slope factor
of 7.6 ±0.8 and 5.4 ±0.7mV for Nav1.5-F1571L and Nav1.5,
respectively (Figure 3C). Co-expression with the β1 subunit did
not rescue the effect of the variant, and Nav1.5-F1571L + β1
displayed a significant 8.3-mV hyperpolarizing shift compared to
Nav1.5+ β1 (P= 0.003), yielding inactivation curves with a V1/2
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FIGURE 3 | Inactivation properties of WT Nav1.5 and Nav1.5-F1571L alone or co-expressed with β1. (A) Displayed from left to right are the representative whole-cell
inactivation recordings of WT Nav1.5 + β1 and Nav1.5-F1571L + β1. The INa were elicited with the pulse protocol shown underneath the traces. (B) The time
constants of channel inactivation for WT Nav1.5 (black circles, n = 5), WT Nav1.5 + β1 (gray circles, n = 12), Nav1.5-F1571L (full red inverted triangles, n = 9), and
Nav1.5-F1571L + β1 (open red inverted triangles, n = 12). The values shown are means ± SEM. (C) Voltage dependence of channel inactivation obtained by plotting
the normalized current amplitudes at −10mV, elicited after 500ms of conditioning pre-pulse depolarization, as a function of the pre-pulse potential. (D) Displayed
from left to right are the representative whole-cell recordings of recovery from inactivation of WT Nav1.5 + β1 and Nav1.5-F1571L + β1. The protocol used is shown
underneath the traces. (E) Graph representing the recovery from inactivation, sampled after 500ms from induction of inactivation.
of −93 ± 2mV (n = 12) and −84 ± 2mV (n = 12), combined
with a slope factor of 7.2 ± 0.5 and 5.8 ± 0.5mV, respectively (P
= 0.04).
As the onset of inactivation was slowed in the variant,
we observed also a slowed recovery from inactivation. The
time constants of recovery from inactivation revealed a slower
recovery for the variant channel compared to WT (P < 0.001),
which was not rescued by co-expression with the β1 subunit
(P < 0.001) [Nav1.5: 7.4 ± 0.1ms (n = 6); Nav1.5-F1571L:
15.2 ± 0.1ms (n = 12); Nav1.5+ β1: 5.2 ± 0. 2ms (n = 10);
Nav1.5-F1571L+ β1: 13± 0.1ms (n= 15)] (Figures 3D,E).
As this patient’s severe phenotype seems to be associated with
Nav1.5-F1571L displaying a hyperpolarizing shift in the voltage
dependence of inactivation, we explored if we could restore the
variant’s voltage dependence of inactivation towardWT values by
drug/toxin addition. The peptide toxin nemertide α-1 seemed to
be a good candidate as it was reported to have a decelerating effect
on the inactivation process of human sodium channels without
influencing the parameters of activation and INa density (17).
Two minutes of perfusion of 5µM of nemertide α-1 induced a
steady-state modification of INa inactivation of both Nav1.5+ β1
and the variant p.F1571L+ β1 (Figure 4A). Upon this nemertide
α-1 addition, we observed a 16-fold slowing in the inactivation
kinetics of Nav1.5+ β1; at 0mV, the time constant of inactivation
slowed from 0.47 ± 0.04ms in the absence of nemertide α-1
to 7.62 ± 1.18ms with nemertide α-1 (n = 6; P = 0.0002).
The variant Nav1.5-F1571L + β1 also reported a significant 3-
fold slowing of inactivation (P = 0.002) displaying at 0mV a
time constant of 2.22 ± 0.57ms in the absence of nemertide
α-1 and 5.82 ± 0.68ms in its presence (n = 6) (Figure 4B).
Next, we investigated the voltage dependence of inactivation
and observed no significant changes in the V1/2 upon toxin
addition for both Nav1.5+β1 and Nav1.5-F1571L+ β1 (P > 0.5).
In contrast, the slope factors became significantly shallower and
amounted, after toxin modification, to 10.6± 0.8mV (n= 6) and
12.3 ± 1.3mV (n = 6) for Nav1.5 + β1 and Nav1.5-F1571L +
β1, respectively (Figures 4C,D). Due to the shallower slope, the
amount of Nav1.5-F1571L + β1 channel inactivation is reduced
at the physiological relevant resting membrane potential (i.e.,
around−85mV) upon nemertide α-1 addition.
DISCUSSION
BrS is rarely observed in the pediatric population (18–20),
and only 4.3% of symptomatic patients experience their first
malignant ventricular arrhythmic event before the age of 16
years (21). Single heterozygous loss-of-function variants in
SCN5A can cause BrS, cardiac conduction disease, sick sinus
syndrome, dilated cardiomyopathy, and familial atrial fibrillation
or manifest as an ‘overlap syndrome’ of these entities (22).
When SCN5A is affected by two compound variants, this can
result in a significant aggravation of the disease severity and/or
earlier disease onset (5, 23–26). This was also observed in
our proband who experienced his first syncope during physical
activity at around the age of 2 years, probably caused by brady-
arrhythmia in the setting of atrial standstill. Most of the similarly
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FIGURE 4 | Inactivation properties of WT Nav1.5 + β1 and Nav1.5-F1571L +β1 in the presence of nemertide α-1. (A) Displayed from left to right are the
representative whole-cell recordings of WT Nav1.5 + β1 and Nav1.5-F1571L + β1 in control conditions (black tracings) and upon steady-state modification by 5µM
nemertide α-1 (red tracings). The currents were elicited with the pulse protocol shown underneath the traces. Steady-state toxin modulation was achieved after
∼2min. (B) Kinetics of channel inactivation for WT Nav1.5 + β1 (circles) and Nav1.5-F1571L + β1 (inverted triangles) in control conditions (black) and upon
steady-state modification by nemertide α-1 (red) are shown. The values are means ± SEM. (C) The voltage dependence of channel inactivation for WT Nav1.5 + β1
(black symbols) and Nav1.5-F1571L + β1 (red) in control conditions (circles) and upon steady-state modification by nemertide α-1 (inverted triangles) is shown.
(D) Scaled-up view of the voltage dependence of channel inactivation in the physiological range of resting membrane potentials, with a focus on the comparison to
the WT Nav1.5 + β1. Note that, in the presence of nemertide α-1, the amount of inactivated Nav1.5-F1571L + β1 channels (red inverted triangles) is similar to the WT
in control conditions (black circles).
published patients presented with sinus node dysfunction (5, 23,
24, 26). Only Sacilotto et al. reported a patient presenting initially
with atrial flutter and recurrent syncopes without spontaneous
ventricular arrhythmia and who, similarly to our case, presented
a spontaneous BrS type-1 ECG pattern during follow-up (24).
Clinical interventions mostly encompass the implantation of a
pacemaker (5, 23, 24, 26), with additional low-dose aspirin (24)
or oral quinidine (23), and single patient received β-blockers
without pacemaker implantation (25).
In the presented family, heterozygous carriers of the SCN5A
Belgian founder mutation showed characteristic BrS type-1
ECG pattern either after sodium channel blocker challenge
(II:2) or during fever conditions (II:3) but presented no
symptoms (II:2) or syncope at the age of 30 years (II:3).
The proband’s second variant, p.Phe1571Leu, is a missense
variant that we functionally modeled in HEK293 cells. Our
experiments showed that p.Phe1571Leu does not affect current
density, voltage dependence of channel activation, or activation
kinetics (Figures 2C–E). However, it did impair the inactivation
properties, as could be expected from the localization of the
variant in the VSD of DIV, which is known to regulate channel
inactivation (9). On the one hand, the variant slows down
inactivation (Figure 3B), which would suggest a gain-of-function
of the variant. This effect would rather be predicted to lead to
a long-QT syndrome type 3 phenotype (4) but, on the other
hand, the voltage dependence of inactivation of p.Phe1571Leu
displays a significant hyperpolarizing shift (Figure 3C) which, in
physiological conditions, results in a reduction of over 40% in
the availability of Nav1.5 channels at rest (i.e., at −85mV). The
significantly slowed recovery of the mutant channel (Figure 3E)
further reduces the availability of the remaining channels,
exacerbating the effect. This combination obviously leads to a
loss-of-function of INa, explaining the (aggravated) phenotype of
cardiac sodium channelopathy with BrS in the patient.
Interestingly, an almost identical electrophysiological effect
was reported for the SCN5A p.Arg1632His (R1632H) variant (5,
26), located inDIV S4 (Figure 2A) in proximity to p.Phe1571Leu.
Slower inactivation kinetics, delayed recovery from inactivation,
and a hyperpolarizing shift in voltage dependence of inactivation
of similar magnitude (20.7mV) as we observed (18mV) were
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described (26). The heterozygous carriers of this variant had no
symptoms, SSS, ajmalin-induced BrS (5), or first-degree AV block
(25), while the compound heterozygous carriers (with second
SCN5A variant) presented with early-onset SSS (5, 25). This
supports the likely pathogenicity of the p.Phe1571Leu variant
characterized in this study and its causal role in aggravating the
phenotype of the presented case.
Also interesting is that another missense variant at the same
amino acid location, p.Phe1571Cys, has been reported in a
Brugada syndrome patient (27), but no functional analysis was
performed. Although the resulting amino acid change is different,
this could be supportive of our findings as well.
Our experiments with the toxin nemertide α-1 showed that
the WT channels were responding as expected as inactivation
kinetics were slowed down. However, no depolarizing shift in
the voltage dependence of inactivation was observed for the WT
Nav1.5+β1 as was observed for Nav1.5 expressed in Xenopus
laevis oocytes (16). This might be because of a different cell
type and/or the addition of the β1-subunit, which seems to
protect the cells from fluctuations in the voltage dependence of
inactivation. Nevertheless, toxin addition resulted in a shallower
voltage dependence of inactivation (i.e., larger slope factor value)
such that the amount of inactivated Nav1.5-F1571L channels
is reduced at the physiological resting membrane potential
(Figures 4C,D). In the presence of toxin, the amount of available
non-inactivated Nav1.5-F1571L + β1 channels rises from 18%
without toxin to ∼36% (at −85mV), which is similar to
the amount of available WT Nav1.5 + β1 channels. To our
knowledge, this is the first report in which the use of a sodium
channel activator toxin is proposed as a potential remedy for the
pathogenic effect of a SCN5A variant.
Based on these functional experiments, we conclude that the
described p.Phe1571Leu variant is likely pathogenic (15) and,
in the presented case, its de novo occurrence, together with the
SCN5A Belgian founder mutation, explains the severe phenotype
of cardiac sodium channelopathy with BrS.
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